-
Human Capital Report 2024
-
Value Creation Report 2024
-
World Alzheimer’s Month ー Life Goes On 2024
A documentary video portraying the daily life of people living with dementia (in Japanese)
-
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
Learn more
"Diversity, Equity and Inclusion" Page Renewal
Introducing Eisai DE&I: Now and the Future
-
Looking Back on 10 Years Since the Commencement of Free Provision of DEC Tablets
Eisai Staff in Charge Talks About Overcoming Challenges on the Uneven Road by Building Trust in Global Partnerships
-
October 2, 2024
EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA
-
October 1, 2024
-
September 24, 2024
ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS
-
September 24, 2024
-
September 17, 2024
-
September 30, 2024
-
August 5, 2024
-
August 2, 2024
IR “First Quarter Financial Report for the Fiscal Year Ending March 31, 2025”
-
July 31, 2024
IR "Presentation Materials at The Alzheimer’s Association International Conference (AAIC) 2024"
-
July 11, 2024
-
October 3, 2024
EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024
-
June 21, 2024
Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”
-
June 3, 2024
The Naito Museum of Pharmaceutical Science and Industry Listed as “Registered Museum”
-
April 8, 2024
-
October 13, 2023
Sustainability
30 countries 2.36 billion tablets
Number of countries supplied with lymphatic filariasis treatment
and volume supplied (as of June 2024)
Eisai is promoting initiatives for improving access to medicines to contribute to people in developing and emerging countries
